|
Hemodyne, Inc.
Defining
Hemostatic Risk
BIBLIOGRAPHY
Sections:
Assay
Development
Platelet Contractile Force
1. Carr, M.E., and Zekert, S.L.: Measurement of
Platelet Mediated-Force Development during Plasma Clot Formation.
American Journal of the Medical Sciences 302:13-18,1991.
2. Carr, M.E. Measurement of platelet force: the
Hemodyne7
Hemostatic Analyzer. Clinical Laboratory Management Review
9:312-320,1995.
3. Carr, M.E., and Zekert, S.L.: Platelet mediated
clot retraction is temperature dependent - studies with a new
retractometer. American Society of Hematology. Annual Meeting -
Atlanta, Ga. December, 1989. Suppl 1 Blood 74(7):399a,ABS#1525,1989.
4. M. Carr, E. J. Martin. Development of Platelet
Contractile Force as a Platelet Specific Hemostatic Marker.
Presented at the New Techniques for the Clinical Laboratory section of
the Eighteenth Annual Hemostasis Update 2001 meeting of Temple
University Hospital. Philadelphia, PA. April 26-28, 2001.
5. M.E. Carr, E.J. Martin. Reproducibility,
daily variation, and the effect of sample age on platelet contractile
force and clot elastic modulus in normal volunteers. XVIIth Congress of
the International Society for Thrombosis and Haemostasis. Washington,
DC. Thrombosis and Haemostasis (Supplement): 396, Aug 1999.
6. M.E.
Carr. Development of platelet contractile force as a research and
clinical measure of platelet function. Accepted for publication in Cell
Biochemistry and Biophysics Vol.38, 2003 
Clot Elastic Modulus
7. Carr, ME, Carr, SL: Fibrin structure and
concentration alter clot elastic modulus but do not alter platelet
mediated force development. Blood Coagulation and Fibrinolysis
6:79-86,1995.
8. Carr, M.E., Zekert, S.L., and Jolly, M.K. Whole
blood clot elastic modulus as a measure of altered erythrocyte
flexibility in sickle cell disease. Presented at the 1992 Annual
meeting of the American Society of Hematology, Anaheim, CA, December
4-8,1992. Blood 80(Suppl 1):11a(ABS#34),1992.
Fibrinolytic Screen – TCLOT –
Tpa-induced Clot Lysis Time
9. Carr, M.E., Carr, S.L., McCardell, K.A. Use of
TPA-induced clot lysis time (TCLOT) to diagnose abnormal clot structure
and fibrinolysis in a patient with spontaneous bleeding into his leg.
Angiology 47:941-949,1996.
10. O. Topaz, C.Morris, A.J. Minisi, P.K. Mohanty
and M.E. Carr.: Enhancement of t-PA Induced Fibrinolysis with
Laser Energy: In-Vitro Observations. Lasers Med Sci 14:123-128,1999.
11. Carr, M.E., and Zekert, S.L. Continuous
monitoring of platelet function and clot structure during
thrombin-induced clotting and tPA-mediated dissolution of whole blood
clots. Presented at the 1992 Annual meeting of the American Society of
Hematology, Anaheim, CA, December 4-8,1992. Blood 80(Suppl
1):312a(ABS#1237),1992.
12. Carr, M.E., Padgett, A.V., Carr, S.L. Effect of
mechanical stress on tPA-induced blood clot lysis rates. 1994 Annual
Meeting of the American Society of Hematology, Nashville, TN, Dec.
1994. Blood 84(Suppl 1):694a,1994.
PCF(TM) as a Marker of
Thrombin Generation in Whole Blood
13. M.E. Carr, E.J. Martin, S.L. Carr.
Delayed, reduced and inhibited thrombin production reduces platelet
contractile force and results in weaker clot formation. Blood
Coagulation and Fibrinolysis 2002;13:193-197.
14. M.E. Carr, E.J. Martin, S.L. Carr. Delayed,
reduced or inhibited thrombin production reduces platelet contractile
force and results in weaker clot formation. Submitted to the 43rd
annual meeting of the American Society of Hematology, Orlando, FL, Nov
30-Dec 4, 2001.
15. M.E. Carr, J.G. Kuhn, E.J. Martin. Platelet
contractile force and clot elastic modulus as markers of thrombin
generation in a patient with severe factor VII deficiency undergoing
treatment with recombinant factor VIIa. 44th annual meeting
of the American Society of Hematology, December 6-10, 2002,
Philadelphia, PA. Blood 100 (Suppl 1):108b,2002.
16. M.E. Carr, E.J. Martin, J.G. Kuhn, S. Seremetis.
Effects of recombinant factor VIIa on thrombin generation, platelet
function and clot structure in blood with deficient prothrombin
conversion. 44th annual meeting of the American
Society of Hematology, December 6-10, 2002, Philadelphia, PA. Blood 100
(Suppl 1):87b,2002.
Laboratory
Monitoring of Increased Bleeding Risk
Renal Failure – Acute
17. Carr, M.E., and Zekert, S.L.: Force monitoring
of clot retraction during DDAVP therapy for the qualitative platelet
disorder of uraemia: Report of a case. Blood Coagulation and
Fibrinolysis 2:303-308,1991.
Renal Failure – Chronic
18. Carr, M.E., Zekert, S.L., Marston, A.W.,
Magruder, C., and Kirschbaum, B. Comparison of platelet force
development, a new measure of platelet function, and bleeding time in
chronic hemodialysis patients. Presented at the Spring 1994 meeting of
the American Society of Clinical Pathology, Seattle, WA, April 9-14,
1994. American Journal of Clinical Pathology 101:392(ABS#73),1994.
19. B. Erickson, B.G. Macik. Platelet contractile
force in chronic hemodialysis patients with arterial-venous fistula. 41st
annual meeting of the American Society of Hematology, New Orleans, LA
Dec 3-7, 1999. Blood 94 (Suppl 1): Abst# 3511, 1999.
Platelet Storage Pool Disease
20. Carr, M.E., Hines, S., Carr, S.L., Todd, W.M.,
Taylor, T.L., Mohanty, L. Storage pool disease in CLL: Abnormal
aggregation and secretion without bleeding. American Journal of the
Medical Sciences 313:176-181,1997.
21. Carr Jr., M.E., Hines, S., Carr, S.L., Todd,
W.M., Taylor, T. Acquired platelet storage pool disease in a patient
with chronic lymphocytic leukemia. 1995 annual meeting of the American
Society of Hematology, Seattle, WA. Blood 86(Suppl 1):895a,1995.
Clotting Factor Deficiencies
(hemophilia, etc.)
22. Carr, M.E., Carr, S.L., Tildon, T. and Fisher,
L.M.. Comparison of thrombin- and batroxobin-induced clots reveals
reduced platelet force in clotting factor deficient patients. American
Society of Hematology, San Diego, California, December 5-9, 1997. Blood
90:92b,1997.
23. M.E. Carr, T.P. Loughran, J.A. Cardea,
W.K. Smith, J.G. Kuhn, M.V. Dottore. Successful use of recombinant
Factor VIIa for haemostasis during total knee replacement in a severe
haemophiliac with high titre Factor VIII inhibitor. International
Journal of Hematology 2002;75:95-99.
24. M.E.
Carr, S.L. Carr, T. Tildon, L.M. Fisher, E.J. Martin.
Batroxobin-induced clots exhibit delayed and reduced platelet
contractile force in some patients with clotting factor deficiencies.
Journal of Thrombosis and Haemostasis 1:243-249, 2003.
25. M.E. Carr, E.J. Martin, J.G. Kuhn, S.V.
Seremetis. Effects of recombinant factor VIIa on platelet function and
clot structure in blood with deficient prothrombin conversion. In Press
Thrombosis and Haemostasis 2003.
26. M.E. Carr, J.G. Kukn, E.J. Martin, A.R.
Tidwell, M.K. Hagan. Pseudo-prolongation of the prothrombin time during
treatment for bleeding with recombinant factor VIIa in a patient with a
spontaneous Factor VIII inhibitor. In Press International Journal of
Hematology 2003.
Excessive Fibrinolytic Activity
27. Carr, M.E., Carr, S.L., Massey, G., Trent, D.
Successful application of the tPA-induced clot lysis time (tCLT) in
three patients with previously undiagnosed bleeding diathesis. 1994
Annual Meeting of the American Society of Hematology, Nashville, TN,
Dec. 1994. Blood 84(Suppl 1):674a,1994.
28. Carr, M.E., McCardell, K., Carr, S.L. and
Graham, P. Effect of fibrinogen fragments X, Y and D on plasma clot
elastic modulus and platelet contractile force. American Society of
Hematology, San Diego, California, December 5-9, 1997. Blood 90:92b,1997.
29. G.V. Massey, N.L. Dunn, E.C. Russell and M.E.
Carr. Successful application of the TPA-induced clot lysis time (tCLT)
in pediatric patients with previous undiagnosed bleeding diathesis.
Presented at the Virginia Society of Hematology and Oncology, Virginia
Beach, VA, June, 1997.
Laboratory
Monitoring of Increased Thrombotic Risk
Coronary Artery Disease
30. Greilich, P.E., Carr, M.E., Zekert, S.L., Dent,
R.M.: Quantitative Assessment of Platelet Function and Clot Structure
in Patients with Severe Coronary Artery Disease. American Journal of
the Medical Sciences 307:15-20,1994.
31. A. Krishnaswami, M.E. Carr, R.L. Jessie, M.
Kontos, A.J. Minisi, J.P. Ornato, G.W. Vetrovec, E.J. Martin. Patients
with coronary artery disease who present with chest pain have
significantly elevated platelet contractile force and clot elastic
modulus. Submitted for publication.
32. Greilich, P.E., and Carr, M.E. Effects of
aspirin on clot structure and fibrin-platelet interactions in patients
with severe coronary artery disease. Presented at the 1992 Annual
meeting of the American Federation of Clinical Research, Baltimore, MD,
May 1-4,1992. Clinical Research 40(2):241A,1992.
33. A. Krishnaswami, M.C. Kontos, E.J. Martin, R.L.
Jesse, G.W. Vetrovec and M.E. Carr. Platelet contractile force
and clot elastic modulus are abnormal in high risk chest pain patients
in the emergency department. 41st annual meeting of the
American Society of Hematology, New Orleans, LA Dec 3-7, 1999. Blood 94
(Suppl 1):69b,1999.
34. A. Krishnaswami, S.L. Carr, M.E. Carr, R.L.
Jessee, M.C. Kontos. The clinical utility of assessing platelet
activity by measurement of force in emergency department patients with
chest pain. American College of Cardiology 48th Annual Scientific
Session. March 7-10, 1999.
35. A. Krishnaswami, M.E. Carr, R. L. Jesse,
M.Kontos, A.J. Minisi, J.P. Ornato, G.W. Vetrovec, E.J. Martin.
Patients with coronary artery disease who present with chest pain have
significantly elevated platelet contractile force. XVIIth Congress of
the International Society for Thrombosis and Haemostasis. Washington,
DC. Aug 14-21,1999. Thrombosis and Haemostasis (Supplement): 162, Aug
1999.
36. A. Krishnaswami, M.E. Carr, R.L. Jessie, M. Kontos,
A.J. Minisi, J.P. Ornato, G.W. Vetrovec, E.J. Martin. Patients with
coronary artery disease who present with chest pain have significantly
elevated platelet contractile force and clot elastic modulus.
Thrombosis and Haemostasis 88:739-44,2002
Multiple Myeloma
37. Carr, M.E., Zekert, S.L.: Abnormal clot
retraction, altered fibrin structure, and normal platelet function in
multiple myeloma. American Journal of Physiology (Heart Circ. Physiol.
35) 266:H1195-H1201,1994.
38. Carr, M.E., and Zekert, S.L. Purified polyclonal
IgG and monoclonal myeloma-induced IgG alter fibrin structure and clot
retraction in plasma gels. Submitted to the American Society of
Hematology - Annual Meeting - Denver, Dec. 1991. Blood 78 (Suppl
1):482a (ABS# 1920),1991.
39. Carr, M.E., and Zekert, S.L. Abnormal clot
retraction in multiple myeloma is caused by altered fibrin structure
and increased clot elastic modulus, not platelet dysfunction. Presented
at the 1992 Annual meeting of the American Society of Hematology, Anaheim,
CA, December 4-8,1992. Blood 80(Suppl 1):325a(ABS#1289),1992.
Diabetes Mellitus
40. M.E. Carr: Diabetes Mellitus: A Hypercoagulable
State. Journal of Diabetes and its Complications 15:44-54,2001.
41. M.E. Carr, A.
Krishnaswami, E.J. Martin. Platelet contractile force (PCFTM ) and clot elastic modulus
(CEM) are elevated in diabetic patients with chest pain. Diabetic
Medicine 19:862-866, 2002.
42. M. Carr, A. Krishnaswami, E. Martin. Elevated
platelet contractile force (PCFTM
) in diabetic patients – a potential marker of increased thrombotic
risk. Presented at the XVIII Congress of The International Society on
Thrombosis and Haemostasis, Paris, France, July 6-12, 2001. Thrombosis
and Haemostasis Abs # P375, Supplement July 2001.
Thromboangiitis Obliterans – Buerger’s Disease
43. M.E. Carr, M.H. Hackney, S.J. Hines, S.P.
Heddinger, S.L. Carr, E. J. Martin. Enhanced platelet force development
despite drug induced inhibition of platelet aggregation in patients
with thromboangiitis obliterans. Vascular and Endovascular Surgery
36:473-480, 2002.
Laboratory
Monitoring of Platelet Viability
44. Alving, B.M., Reid, T.J., Fratantoni, J.C.,
Finlayson, J.S. Frozen platelets and platelet substitutes in
transfusion medicine. Transfusion 37:866-876,1997.
45. Reid, T., Snider, R., Hartman, K., Greilich,
P.E., Carr, M.E., Alving, B.M.: A Method for the quantitative
assessment of platelet-induced clot retraction and clot strength in
fresh and stored platelets. Vox Sanguinis 75:270-277,1998.
46. Reid, T.J., Greilich, P.E., Carr Jr., M.E.,
Alving, B. Quantitative clot retraction: a method for assessing the
function of fresh and stored platelets and GPIIb/IIIa receptors. 1994
Annual Meeting of the American Society of Hematology, Nashville, TN,
Dec. 1994. Blood 84(Suppl 1):463a,1994.
47. S.W. Rothwell, P. Maglasang, T.J. Reid, M.
Gorogias, and C. Krishnamurti. Correlation of in vivo and in vitro
functions of fresh and stored human Platelets. 41st annual
meeting of the American Society of Hematology, New Orleans, LA Dec 3-7,
1999. Blood 94 (Suppl 1): Abst#2059, 1999.
48. M.E. Carr Jr.: Instrumentation to Assess
Platelet Function In Vitro. Presented at: Frozen Platelets and Platelet
Substitutes in Transfusion Medicine. Uniformed Services University of
Health Sciences. Bethesda, Maryland, March 7-8,1996.
49. M.E. Carr, and E.J. Martin. How long does a
platelet survive? Platelet contractile force as a measure of platelet
viability. 41st annual meeting of the American Society of
Hematology, New Orleans, LA Dec 3-7, 1999. Blood 94 (Suppl
1):117b,1999.
Laboratory
Monitoring - Platelet Function
50. Carr, M.E. In vitro assessment of platelet
function. Transfusion Medicine Reviews 11:106-115,1997.
51. O. Topaz, A. J. Minisi, N.L. Bernardo, R.A.
McPherson, E. Martin, S.L. Carr, M.E. Carr: Effect of Excimer Laser
emission on platelet aggregation: the “stunned platelet” phenomenon.
Thrombosis and Haemostasis 86:1087-1093,2001.
52. Carr Jr., M.E., Carr, S.L., Yanovich, S. Is
platelet dysfunction clinically significant in stem cell disorders?
Abnormal platelet aggregation with normal force development in
essential thrombocytosis. 1995 annual meeting of the American Society
of Hematology, Seattle, WA. Blood 86(Suppl 1):792a,1995.
53. M. Gorogias, T.J. Reid. Clotting times and
platelet induced clot retraction of human plasma and platelets:
Comparison of thrombin derived from different animal species and
implications for novel hemostatic agents. 41st annual
meeting of the American Society of Hematology, New Orleans, LA Dec 3-7,
1999. Blood 94 (Suppl 1): Abst# 3555, 1999.
Monitoring
of Drug Effects
Heparin
54. Carr, M.E., Carr, S.L.: At high heparin
concentrations, protamine concentrations which reverse heparin
anticoagulant effects are insufficient to reverse heparin anti-platelet
effects. Thrombosis Research 75:617-630,1994.
55. Carr, M.E., Carr, S.L., Greilich, P.E. Heparin
Ablates Force Development during Platelet Mediated Clot Retraction.
Thrombosis and Haemostasis 75:674-678,1996.
56. M.E. Carr, S.L. Carr, V. Roa and K.A.
McCardell. Aprotinin counteracts heparin-induced inhibition of platelet
force. Accepted for publication in Thrombosis Research.
57. Carr, M.E., Zekert S.L., and Greilich, P.E.
Heparin totally ablates force development during platelet mediated clot
retraction. Presented at the 1992 Zimmerman conference on Progress in
Vascular Biology, Hemostasis and Thrombosis. February 27-29, 1992.
58. Carr, M.E., Park, A., Zekert, S.L., Marques, D.,
Goldman, I.D., and Sobel M. Anticoagulant and antiplatelet activities
of heparin and low molecular weight derivatives. 1993 Annual meeting of
the American Society of Hematology, St. Louis, MO, December 3-7, 1993.
Blood 82(Suppl 1):603a(ABS#2396),1993.
GP IIb/IIIa blockade –
(Integrilin, Reopro, Aggrastat)
59. Carr, M.E., Carr S.L., Hantgan, R.R., Braaten,
J.: Glycoprotein IIb/IIIa Blockade Inhibits Platelet Mediated Force
Development and Reduces Gel Elastic Modulus. Thrombosis and Haemostasis
73:499-505,1995.
60. Greilich, P.E., Alving, B.M., O=Neill, K.L., Chang,
A.S., Reid, T.J. A modified thromboelastographic method for monitoring
c7E3 Fab in Heparinized Patients. Anesthesia and Analgesia
84:31-8,1997.
61. P.E. Greilich, B.M. Alving, D. Longnecker, M.E.
Carr, C.W. Whitten, A.S. Chang, and T.J. Reid. Near-site monitoring of
the antiplatelet drug ABCIXIMAB using the Hemodyne7 analyzer and
modified Thromboelastograph7.
Journal of Cardiothoracic and Vascular Anesthesia 13:58-64,1999.
62. Carr, M.E., Zekert, S.L., and Strony J. Effects
of glycoprotein IIb/IIIa blockade on force development during platelet
mediated clot retraction. Presented at the 1992 Annual meeting of the
American Federation of Clinical Research, Baltimore, MD, May 1-4,1992.
Clinical Research 40(2):378A,1992.
63. J. Mitchell, M.E. Carr. Measurement of platelet
contractile force allows in vitro comparison of Reopro7, Integrilin7 and Aggrastat7 blockade of GP
IIb/IIIa in clotting whole blood. Fourth annual meeting of the
International Academy of Clinical and Applied Thrombosis/Hemostasis.
Dallas, TX. Nov 12-14, 1998.
64. P.E. Greilich, M.E. Carr, M.V. Cooley, D.N.
Harris, S.L. Carr, C.W. Whitten. Dose dependent effects of c7E3 Fab on
modified thromboelastography in healthy volunteers. Accepted for
presentation at the 72nd Annual Meeting of the International Anesthesiology
Research Society - Orlando, FL March 7-11, 1998.
65. J. Mitchell, M.E. Carr. Platelet contractile
force declines across the therapeutic concentration range of Reopro7: Potential for
simultaneous measurement of both drug levels and therapeutic response.
Fourth annual meeting of the International Academy of Clinical and
Applied Thrombosis/Hemostasis. Dallas, TX. Nov 12-14, 1998.
IV Contrast Media
66. Carr, M.E., Carr, S.L., Merten, S.R.: Effects of
Ionic and Nonionic Contrast Media on Clot Structure, Platelet Function
and Thrombolysis Mediated by Tissue Plasminogen Activator in Plasma
Clots. Haemostasis 25:172-181,1995.
67. Carr, M.E., Carr, S.L., Merten, S.R. Effects of
ionic and non-ionic contrast media on clot structure, platelet function
and tPA-mediated thrombolysis in plasma clots. 1994 Annual Meeting of
the American Society of Hematology, Nashville, TN, Dec. 1994. Blood
84(Suppl 1):674a,1994.
Aprotinin
68. M.E. Carr,
S.L. Carr, V. Roa and K.A. McCardell. Aprotinin counteracts
heparin-induced inhibition of platelet force. Submitted to Thrombosis
Research.
69. Carr, M.E., and Zekert, S.L.: The impact of
fibrin fiber structure on platelet mediated clot retraction.
American Society of Hematology. Annual Meeting - Atlanta, Ga. December,
1989. Suppl 1 Blood 74(7):399a,ABS#1524,1989.
70. Carr Jr., M., Carr, S., Roa, V. Aprotinin
prevents heparin blockade of platelet force development. Presented at
Experimental Biology '96 - The American Physiology Society, April
14-17, 1996, Washington, D.C.
71. McCardell, K.A., Carr, S.L., Carr, M.E.
Aprotinin can reverse heparin mediated suppression of platelet force
development. Presented at Biomedicine '96 - AFCR, May 3-6, 1996,
Washington, D.C. Journal of Investigative Medicine 44:287A,1996.
72. McCardell, K.A., Carr, S.L., Carr, M.E.
Aprotinin augments protamine sulfate reversal of heparin antiplatelet
effects. Presented at Biomedicine '96 - AFCR, May 3-6, 1996,
Washington, D.C. Journal of Investigative Medicine 44:212A,1996.
73. McCardell, K.A., Carr, S.L., Carr, M.E.
Aprotinin can reverse heparin anti-platelet effects. Presented to the
Virginia Society of Hematology, Virginia Beach, VA, June 1996.
DDAVP
74. Carr, M.E., and Zekert, S.L.: Force monitoring
of clot retraction during DDAVP therapy for the qualitative platelet
disorder of uremia: Report of a case. Blood 76 (Suppl 1):450a (ABS#
1791), 1990.
75. Greilich, P.E., Carr, M.E., Zekert, S.L. The
effects of desmopressin acetate (DDAVP) on platelet force development
in patients bleeding excessively after cardiopulmonary bypass (CPB).
Presented at the 1994 Annual Meeting of the American Federation of
Clinical Research, Baltimore, Maryland, May, 1994. Clinical
Research 42(2):186A,1994.
Protamine Sulfate
76. Carr, M.E., and Dent, R.M. Protamine sulfate
alters fibrin assembly and structure resulting in enhanced
fibrinolysis. 1992 Annual meeting of the American Federation of
Clinical Research, Baltimore, MD, May 1-4,1992. Clinical Research
40(2):420A,1992.
77. Carr, M.E., Zekert, S.L., and Padgett, A.V.
Protamine reverses anticoagulant effects of heparin at doses
insufficient to reverse antiplatelet effects. Presented at the 1993
Annual meeting of the American Society of Hematology, St. Louis, MO,
December 3-7, 1993. Blood 82(Suppl 1):147a(ABS#575),1993.
Aspirin
78. Greilich, P., Carr, M.E., Zekert, S., and
Nakatsuka, M. Platelet force development is sensitive to
aspirin-induced alterations in clot structure and function in patients
with coronary artery disease. Presented at the Annual Meeting of the
American Society of Anesthesiology, October, 1992.
Non-Heparin
Anti-thrombin Drugs (refludan, argatroban, etc.)
79. Carr, M.E., and Zekert, S. Effect of non-heparin
thrombin antagonists on platelet force development during clot
retraction. Presented at the XIVth Congress of the International
Society of Thrombosis and Haemostasis. 1993. Thromb Haemostas
69:1241,1993.
80. M.E. Carr, P. Angchaisuksiri, S.L. Carr, E.J.
Martin. Effect of non-heparin thrombin antagonists on thrombin
generation, platelet function and clot structure in whole blood.
Submitted to Cell Biochemistry and Biophysics.
e-Aminocaproic
Acid (EACA)
81. Carr Jr., M.E., Angchaisuksiri, P., Carr, S.L.
Effect of e-aminocaproic acid
(EACA) on clot structure and platelet function during tPA mediated clot
dissolution. 1995 annual meeting of the American Society of Hematology,
Seattle, WA. Blood 86(Suppl 1):895a,1995.
Adenosine A2-Receptor
Agonist (NECA)
82. Carr Jr., M.E., Carr, S.L., Padgett, A.V.,
Dumas, D.P. Effect of adenosine A2-receptor agonist (NECA)
on platelet function, fibrin structure and plasma clot dissolution.
1995 annual meeting of the American Society of Hematology, Seattle, WA.
Blood 86(Suppl 1):895a,1995.
AntiThrombin
III Concentrate
83. Carr Jr., M.E., Angchaisuksiri, P., Carr, S.L.,
Barnes, J. Effect of antithrombin III concentrate, alone or with
heparin, on clot structure and platelet function. 1995 annual meeting
of the American Society of Hematology, Seattle, WA. Blood 86(Suppl
1):866a,1995.
Dermatan Sulfate
84. Carr, M.E., Monge-Meberg P., McCardell K., Carr,
S.L. Dermatan sulfate suppresses platelet force as it prolongs the
APTT. Blood 88:79b,1996.
Dehydroepiandrosteron
(DHEA)
85. Carr, M.E., Carr, S.L., Monge-Meberg, P.,
Williams, T.K. and Nestler, J: Effects of dehyroepiandrosteron (DHEA)
on platelet function, fibrinolysis and clot structure. American Society
of Hematology, San Diego, California, December 5-9, 1997. Blood
90:92b,1997.
Thrombopoietin
86. Carr, M.E., Carr, S.L., McCardell, K. and
Dessypris, E.N. Differential effects of thrombopoietin and stem cell
factor on platelet contractile force. American Society of
Hematology, San Diego, California, December 5-9, 1997. Blood 90:67b,1997.
Nitric Oxide
(NO) Generators [NONOates]
87. T.J. Reid, M.A. Cutting, M. Clear, R.L. Snider.
Kinetics of NONOates (Nitric oxide (NO) generators) is the same in
plasma and buffer- investigations of platelet function. XVIIth Congress
of the International Society for Thrombosis and Haemostasis.
Washington, DC. Thrombosis and Haemostasis (Supplement): 635, Aug 1999.
Platelet Activating Factor
88. M.E. Carr, and E.J. Martin. In vitro addition of
platelet activating factor to whole blood does not alter platelet
contractile force. 41st annual meeting of the American
Society of Hematology, New Orleans, LA Dec 3-7, 1999. Blood 94 (Suppl
1):63b,1999.
Surgical Monitoring
Cardiopulmonary Bypass
89. Greilich, P.E., Carr, M.E., Carr, S.L., Chang,
A.S.: Reductions in Platelet Force Development by Cardiopulmonary
Bypass Are Associated with Hemorrhage. Anesthesia and Analgesia
80:459-465,1995.
90. Skubas, N., Despotis, G.J.: Intraoperative
Diagnosis and Therapy of Hemostasis Abnormalities with Cardiac Surgery.
In Hemostasis In Cardiac Surgery, Chapter 7, pg. 91-188. Futura
Publishing Company, 1999.
91. P. Greilich,
C. Brouse, J. Beckham, M. Jessen, E. Martin, M. Carr. Reductions in
platelet contractile force correlate with duration of cardiopulmonary
bypass and blood loss in patients undergoing cardiac surgery. Accepted
for publication - Thrombosis Research.
92. Greilich, P.E., and Carr, M.E. Evaluation of
force development during platelet mediated clot retraction in patients
undergoing cardiopulmonary bypass surgery. 1992 Annual meeting of the American
Federation of Clinical Research, Baltimore, MD, May 1-4,1992. Clinical
Research 40(2):401A,1992.
93. Greilich, P.E., Carr, M.E., Zekert, S.L., and
Chang, A. The effect of cardiopulmonary bypass on platelet force
development and it's association with early post bypass hemorrhage.
Submitted to the 1994 Annual Meeting of the Society of Cardiovascular
Anesthesiologists, Montreal, Canada, April 23-27,1994.
94. Greilich, P.E., Carr Jr., M.E. Reductions in
platelet force development by cardiopulmonary bypass are associated
witsh hemorrhage. Presented at the 1994 annual meeting of the American
Society of Anesthesiologists. San Francisco, CA. October 17, 1994.
Anesthesiology 81:A551,1994.
95. P.E. Greilich, R. Ravi Kumar, L.K. Douning, J.M.
DiMaio, M. Augustus, M.E. Carr. Effect of cardiopulmonary bypass (CPB)
time on the degree of platelet dysfunction. 42nd annual
meeting of the American Society of Hematology, San Francisco, CA, Dec
1-5, 2000. Blood 96 (Suppl 1):65b,2000.
96. Carr, M.E., Carr, S.L., Greilich, P.E.
Comparison of Hemodyne7
Hemostasis Analyzer and Thromboelastogram7
abilities to detect effects of altered fibrin and platelet
concentrations. Blood 88:58b,1996.
97. P. Greilich, J. Beckham, M. Augustus, S. Becker,
A. Estrera, M. Carr. Reductions in platelet contractile force following
cardiopulmonary bypass (CPB) surgery correlate with duration of CPB and
decreases in fibrinogen receptor expression. Presented at the XVIII
Congress of The International Society on Thrombosis and Haemostasis, Paris,
France, July 6-12, 2001. Thrombosis and Haemostasis Abs # P380,
Supplement July 2001.
98. P.E. Greilich, M.E. Carr, C. Brouse, E.J.
Martin, J. Beckham, M. Augustus, A. Estrera. Reductions in Platelet
Contractile Force correlate with duration of cardiopulmonary bypass and
blood loss in patients undergoing cardiac surgery. Submitted to the 43rd
annual meeting of the American Society of Hematology, Orlando, FL, Nov
30-Dec 4, 2001.
99. P. Greilich, C. Brouse, J. Beckham, M. Jessen,
E. Martin, M. Carr. Reductions in platelet contractile force
correlate with duration of cardiopulmonary bypass and blood loss in
patients undergoing cardiac surgery. Thrombosis Research 105:523-529,
2002.
BioHemostat
– Device for Acute Treatment of Arterial Bleeding
100. M.E. Carr, G. Wnek, K. Cohen, K. Ward, R.
Ivatory, G. Bowlin. The BioHemostat – Acute treatment modality for High
Pressure Bleeding – Changing the Treatment Paradigm to: “Saving the
Patient and Sparing the Limb.” Proceedings o f ATACCC 2001 – Advanced
Technology Applications for Combat Casualty Care. Page 30, Abstract 44.
101. M. Carr, E. Kenawy, J. Layman, G. Wnek, K.
Ward, W. Barbee, M. Tiba. Development of the Biohemostat – a treatment
modality for high pressure bleeding based on super absorbent polymers.
Submitted to the twenty-fifth annual Conference on Shock of the Shock
Society. June 8-11, 2002.
102. M. E. Carr. Development of the BioHemostat – a
treatment modality for high pressure bleeding. Presented a
the ATACCC 2002 meeting. St. Petersburg, FLA.
September 9-11, 2002.
103. M.E. Carr, G. Wnek, D.
Simpson, G. L. Bowlin. Electrospinning of Nanofiber Fibrinogen
Structures. Nano Letters 3,213-216,2003.
|
